Continence is defined as the ability of keeping urine in the bladder between episodes of voluntary micturition. Risk factors are all conditions which lead to increased intraabdominal pressure, especially age and prolonged labour; and neurological diseases. Overactive bladder syndrome is a term used to describe the symptom complex of urinary urgency with or without urge incontinence, usually with frequency and nocturia. Diagnosis of OAB besides medical history, physical exam, urin sample and lower limb neurological exam sometimes include urodynamic testing. According to the newest AUA’s clinical practice guidelines for OAB we have three lines of treatment. The first line of treatment includes conservative management with lifestyle changes and bihevioral therapy (Kegel’s exercises, electrostimulation of pelvic floor muscles and pelvic floor muscle training – PFMT) . The second line of treatment are antimuscarinic/anticholinergic drugs and sympathomimetic/adrenergic-agonist drugs. Antimuscarinics include oxybutynin, tolterodine, trosipum chloride, propiverine, fesoterodine and solifenancin. Trospium chloride’s activitiy is mostly located in the peripheria because it is the only medicament which doesn’t cross BBB and has minor effects on CNS. Whereas antimuscarinics are gold standard of medicamentous treatment of OAB, new sympathomimetic medicament called mirabegron is as efficient as antimuscarincs, has less side effects and better persistance. The third line of treatment is used for patients with refractory OAB. It includes botulinum toxin A, sacral nerve stimulation and posterioir tibial nerve stimulation.